Boston Scientific ((BSX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Boston Scientific is conducting a study titled ‘A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain.’ The study aims to assess the real-world clinical outcomes, economic value, and technical performance of its neurostimulation systems for pain management. This research is significant as it evaluates the long-term effectiveness of these systems in routine clinical practice.
The intervention being tested is a neurostimulation system, a device designed to manage pain by delivering electrical stimulation to the nervous system. The study involves a trial stimulation period, followed by a permanent implant for subjects who respond positively.
This observational study follows a cohort model with a prospective time perspective. The primary purpose is to gather data on the effectiveness and economic value of the neurostimulation systems in a real-world setting.
The study began on October 30, 2012, and is currently recruiting participants. The most recent update was submitted on October 13, 2025. These dates are crucial as they indicate the study’s ongoing nature and the timeline for data collection and analysis.
The update on this study could influence Boston Scientific’s stock performance positively, as successful results may enhance investor confidence and market position. It is essential to consider the competitive landscape, as advancements in neurostimulation technology could impact the broader industry.
The study is ongoing, with further details available on the ClinicalTrials portal.